Fredrik Nils Albach

7PUBLICATIONS
30CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityAutoimmunityHaematological tumoursRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 09, 2024
Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis.

Fredrik N Albach, Christian Geier, Christian Keicher

|Jul 05, 2024
Prophylactic antibodies inhibit spike-specific T and B cell responses after COVID-19 vaccination.

Henrik E Mei, Axel Ronald Schulz, Heike Hirseland

|Jan 04, 2023
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease.

Leonie Maria Frommert, Amanthi Nadira Arumahandi de Silva, Jan Zernicke

|Jan 04, 2023
Mild COVID-19 despite inadequate antibody response after repeated vaccinations in rheumatic disease patients with rituximab-induced B cell depletion: a case series.

Alexander Ten Hagen, Elisa Habermann, Sandra Hermann

|Oct 10, 2022
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.

Elisa Habermann, Lutz Gieselmann, Pinkus Tober-Lau

|Mar 15, 2022
Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases.

Amanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Fredrik N Albach

Pageof 2

Frequent Collaborators

5 joint publications

Gerd-Rüdiger Burmester

5 joint publications

Robert Biesen

4 joint publications

Alexander Ten Hagen

3 joint publications

Elisa Habermann